Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcastEpisode 35 of the pharmaphorum podcast hears from Michael Smyth about Galapagos UK and joining the company as Share XGalapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/galapago-uk-michael-smyth-rna/
Deep Dive: Market AccessIt’s fair to say this is the most interesting time ever for market access. Not only has COVID Share XDeep Dive: Market Accesshttps://pharmaphorum.com/views-analysis-market-access/deep-dive-market-access-2021/
The next five years of NICE: Challenges, opportunities, and the future of technology assessmentIf NICE is to remain a “beacon of evidence-based medicine”, it must become more agile, more flexible, and Share XThe next five years of NICE: Challenges, opportunities, and the future of technology assessmenthttps://pharmaphorum.com/views-and-analysis/the-next-five-years-of-nice-challenges-opportunities-and-the-future-of-technology-assessment/
Three pillars of post-pandemic launch excellenceIQVIA’s Sarah Rickwood reviews the launch of innovative medicines in 2020 and outlines three key pillars of activity Share XThree pillars of post-pandemic launch excellencehttps://pharmaphorum.com/views-and-analysis/three-pillars-of-post-pandemic-launch-excellence/
Global impact: How regulatory affairs is shaping development of cutting-edge pharma innovationWhen it comes to developing cutting-edge innovations, Astellas aims to be at the forefront. The pharma organisation prides Share XGlobal impact: How regulatory affairs is shaping development of cutting-edge pharma innovationhttps://pharmaphorum.com/views-and-analysis/global-impact-how-regulatory-affairs-is-shaping-development-of-cutting-edge-pharma-innovation/
NICE methods and process review aims to create fertile ground for innovationThe way NICE reviews new medicines is about to go through its biggest change in years – but Share XNICE methods and process review aims to create fertile ground for innovationhttps://pharmaphorum.com/views-and-analysis/nice-methods-and-process-review-aims-to-create-fertile-ground-for-innovation/
The Brexit deal; shot in the arm or kick in the teeth for the pharma sector?The UK Government and EU Commission trumpeted their Brexit trade deal, struck at the end of December, as Share XThe Brexit deal; shot in the arm or kick in the teeth for the pharma sector?https://pharmaphorum.com/market-access-2/the-brexit-deal-for-the-pharma-sector/
Life sciences must become cloud-first to seize the science of tomorrowIf the power of the life sciences industry to innovate and collaborate were ever in doubt, the speed Share XLife sciences must become cloud-first to seize the science of tomorrowhttps://pharmaphorum.com/views-analysis-digital/life-sciences-must-become-cloud-first-to-seize-the-science-of-tomorrow/
Pharma must adapt to embrace the opportunities of a new-look NHSFundamental changes to the way the NHS is structured and funded are afoot – and pharma needs to Share XPharma must adapt to embrace the opportunities of a new-look NHShttps://pharmaphorum.com/views-and-analysis/pharma-must-adapt-to-embrace-the-opportunities-of-a-new-look-nhs/
